Abstract
The study’s goal is to evaluate the effectiveness of erlotinib in patients with EGFR mutant metastatic non-small cell lung cancer (mNSCLC). The patient's medical data were analyzed retrospectively. Erlotinib's effectiveness was assessed by the radiological response. Survival analyzes were done for prognostic factors. Eighty-five patients were included in the study. 49 (57.6%) of the patients were female, and the average age was 60 (range, 33-85). Exon 19, exon, 21, and other mutati
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
